Journal of Clinical Pathology and Laboratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Clinical Pathology and Laboratory Medicine (2021) Volume 3, Issue 3

Advances in determination of Alzheimerâ??s β-amyloid peptide

Alzheimer’s disease (AD), as the most common progressive neurodegenerative disorder, is pathologically characterized by deposition of extracellular plaque composed of amyloid-β peptide (Aβ). Therefore, the development of reliable assays for Aβ (both monomers and oligomers) are important for the early differential diagnosis of dementia, predicting the progression of AD, as well as monitoring the effectiveness of novel anti-Aβ drugs for AD. Recently, our group has constructed several analytical assays for sensing Aβ (both monomers and oligomers): by using aptamer- and thioninemodified gold nanoparticles (aptamer-Au-Th) as the signing probe, we fabricated an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers; based on metal–organic frameworks as electrochemical signal probes, we developed a sensitive aptasensor for the detection of β-amyloid oligomers; based on the target-mediate aggreation of gold nanoparticle, we constructed a sensitive colorimetric assay for β-amyloid oligomers; based on the specific binding between Cu2+ and Aβ1−40, we proposed a colorimetric assay as well as a fluorescent assay for Aβ1−40 monomer.

Author(s): Yanli Zhou

Abstract PDF

Get the App